Studies of marine sulfated polymannuroguluronate on endothelial cell proliferation and endothelial immunity and related mechanisms.

Anti-proliferation action and enhancement of endothelial cell immunity and related mechanisms by marine sulfated polymannuroguluronate (SPMG) were investigated in the present studies. Endothelial cell proliferation was evaluated by MTT assay. Intercellular adhesion molecule-1 (ICAM-1) expression was analyzed by flow cytometry. The interaction of SPMG with basic fibroblast growth factor (bFGF) was evaluated by surface plasmon resonance. Results showed that SPMG exhibited a significant inhibitory effect against proliferation in both normal human umbilical vein endothelial cells (HUVEC) and bFGF-treated HUVEC, the action of which was completely abrogated by bFGF antibody. SPMG exerted high affinity to bFGF in a multivalent pattern, characterized by one molecule SPMG binding to 3 - 4 molecules of bFGF. Moreover, SPMG enhanced ICAM-1 expression in HUVEC and prevented and restored bFGF-treated downregulation of ICAM-1 expression in HUVEC, the expression of which was not counteracted by bFGF antibody. In conclusion, this is the first report demonstrating that SPMG exerted an anti-proliferation effect dependent on the bFGF-regulated pathway and afforded upregulatory activity on ICAM-1 expression regardless of the involvement of bFGF.

[1]  G. Waksman,et al.  FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. , 1995, Science.

[2]  G. Groenewegen,et al.  Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. , 1996, Blood.

[3]  B. Olwin,et al.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation , 1991, Science.

[4]  R. Odedra,et al.  Low molecular weight angiogenesis factors. , 1991, Pharmacology & therapeutics.

[5]  W. Rath,et al.  Long-term follow-up and prognostic significance of angiogenic basic fibroblast growth factor (bFGF) expression in patients with breast cancer. , 2002, Pathology, research and practice.

[6]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.

[7]  Harold E. Dvorak,et al.  Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors , 1997, Thrombosis and Haemostasis.

[8]  M. Nugent,et al.  Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response. , 2000, Biochemistry.

[9]  D. Ingber,et al.  Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). , 1994, British Journal of Cancer.

[10]  M. Salmivirta,et al.  Selectively Desulfated Heparin Inhibits Fibroblast Growth Factor-induced Mitogenicity and Angiogenesis* , 2000, The Journal of Biological Chemistry.

[11]  G. Groenewegen,et al.  Angiogenesis inhibitors overcome tumor induced endothelial cell anergy , 1999, International journal of cancer.

[12]  I. Clemmensen,et al.  Angiogenic balance in human melanoma: Expression of VEGF, bFGF, IL‐8, PDGF and angiostatin in relation to vascular density of xenografts in vivo , 2000, International journal of cancer.

[13]  J. Richie,et al.  Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. , 1994, Journal of the National Cancer Institute.

[14]  J. Michel,et al.  Heparin and non-heparin-like dextrans differentially modulate endothelial cell proliferation: in vitro evaluation with soluble and crosslinked polysaccharide matrices. , 2002, Journal of biomedical materials research.

[15]  J. Folkman.  Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. , 1990, Cancer metastasis reviews.

[16]  A. Griffioen,et al.  Angiogenesis modulates the tumour immune response , 1998, International journal of experimental pathology.

[17]  G. Zugmaier,et al.  Polysulfated Heparinoids Selectively Inactivate Heparin‐Binding Angiogenesis Factors , 1999, Annals of the New York Academy of Sciences.

[18]  Jeffrey D. Esko,et al.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor , 1991, Cell.

[19]  R. Linhardt,et al.  Nature of the interaction of heparin with acidic fibroblast growth factor. , 1993, Biochemistry.

[20]  H. Nagawa,et al.  Suppressive effect of basic fibroblast growth factor on transendothelial emigration of CD4(+) T-lymphocyte. , 1994, Cancer research.

[21]  D C Rees,et al.  Heparin Structure and Interactions with Basic Fibroblast Growth Factor , 1996, Science.

[22]  M. Jaye,et al.  Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation , 1994, Cell.

[23]  J. Gamble,et al.  A new assay for the measurement of the attachment of neutrophils and other cell types to endothelial cells. , 1988, Journal of immunological methods.

[24]  K. Flanders,et al.  Endothelial cells synthesize basic fibroblast growth factor and transforming growth factor beta. , 1988, Growth factors.

[25]  W. Risau,et al.  Induction of vasculogenesis and hematopoiesis in vitro. , 1992, Development.

[26]  M. Klagsbrun.  Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. , 1992, Seminars in cancer biology.

[27]  G. Groenewegen,et al.  Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. , 1996, Cancer research.